Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Saran

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 13, 2006
Fractionated stereotactic conformal radiotherapy following conservative surgery in the control of craniopharyngiomasGiuseppe Minniti, Frank Saran, Daphne Traish, et al.
Journal of Neuro-Oncology|November 17, 2021
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trialFrank Saran, Liam Welsh, Allan James, et al.
Pituitary|July 3, 2026
Clinician decision-making in non-functioning pituitary adenomas: an Australian and New Zealand interdisciplinary survey studyEdward Mignone, Frank Saran, Alkis Psaltis, et al.
Oncotargets and Therapy|April 15, 2022
Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to AfatinibScott Owen, Scheryll Alken, Jad Alshami, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 18, 2014
Hyperfractionated Accelerated Radiotherapy (HART) with maintenance chemotherapy for metastatic (M1-3) Medulloblastoma--a safety/feasibility studyRoger E Taylor, Andrew J Howman, Keith Wheatley, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 26, 2016
Slice Encoding for Metal Artefact Correction in magnetic resonance imaging examinations for radiotherapy planningMaria A Schmidt, Rafal Panek, Ruth Colgan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 31, 2009
Impact of radiotherapy parameters on outcome for patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 studyRoger E Taylor, Paul H J Donachie, Claire L Weston, et al.
Current Oncology (Toronto, Ont.)|June 26, 2024
Survival after Stereotactic Radiosurgery in the Era of Targeted Therapy: Number of Metastases No Longer MattersJames de Boisanger, Martin Brewer, Matthew W Fittall, et al.
World Neurosurgery|January 24, 2026
Surgical Outcomes in Knosp grade 3 or 4 macroprolactinomas: What role does debulking surgery play?Christopher Ovenden, Victoria Tan, David J Torpy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade gliomaMichael Brada, Sally Stenning, Rhian Gabe, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 13, 2006
Fractionated stereotactic conformal radiotherapy following conservative surgery in the control of craniopharyngiomasGiuseppe Minniti, Frank Saran, Daphne Traish, et al.
Journal of Neuro-Oncology|November 17, 2021
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trialFrank Saran, Liam Welsh, Allan James, et al.
Pituitary|July 3, 2026
Clinician decision-making in non-functioning pituitary adenomas: an Australian and New Zealand interdisciplinary survey studyEdward Mignone, Frank Saran, Alkis Psaltis, et al.
Oncotargets and Therapy|April 15, 2022
Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to AfatinibScott Owen, Scheryll Alken, Jad Alshami, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 18, 2014
Hyperfractionated Accelerated Radiotherapy (HART) with maintenance chemotherapy for metastatic (M1-3) Medulloblastoma--a safety/feasibility studyRoger E Taylor, Andrew J Howman, Keith Wheatley, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 26, 2016
Slice Encoding for Metal Artefact Correction in magnetic resonance imaging examinations for radiotherapy planningMaria A Schmidt, Rafal Panek, Ruth Colgan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 31, 2009
Impact of radiotherapy parameters on outcome for patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 studyRoger E Taylor, Paul H J Donachie, Claire L Weston, et al.
Current Oncology (Toronto, Ont.)|June 26, 2024
Survival after Stereotactic Radiosurgery in the Era of Targeted Therapy: Number of Metastases No Longer MattersJames de Boisanger, Martin Brewer, Matthew W Fittall, et al.
World Neurosurgery|January 24, 2026
Surgical Outcomes in Knosp grade 3 or 4 macroprolactinomas: What role does debulking surgery play?Christopher Ovenden, Victoria Tan, David J Torpy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade gliomaMichael Brada, Sally Stenning, Rhian Gabe, et al.
Pageof 8